અહેવાલો

Lorlatinib is a 3rd generation TKI developed by Pfizer.  In England, Wales and Northern Ireland it is licensed for use after progression on a 2nd generation TKI.  In Scotland, it is also licensed for 1st line treatment.  The recommended dose is 100mg taken daily.